Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
No Thumbnail Available
Issue Date
2018
Our author(s)
Tsang, D.
Department
Keywords
Language
English
Publisher
Elsevier
ISSN
2588-9311
eISSN
ISBN
Type
Article
Citation
Woods, B. S., Sideris, E., Sydes, M. R., Gannon, M. R., Parmar, M. K. B., Alzouebi, M., Attard, G., Birtle, A. J., Brock, S., Cathomas, R., Chakraborti, P. R., Cook, A., Cross, W. R., Dearnaley, D. P., Gale, J., Gibbs, S., Graham, J. D., Hughes, R., Jones, R. J., Laing, R., Mason, M. D., Matheson, D., Mclaren, D. B., Millman, R., O'sullivan, J. M., Parikh, O., Parker, C. C., Peedell, C., Protheroe, A., Ritchie, A. W. S., Robinson, A., Russell, J. M., Simms, M. S., Srihari, N. N., Srinivasan, R., Staffurth, J. N., Sundar, S., Thalmann, G. N., Tolan, S., Tran, A. T. H., Tsang, D., Wagstaff, J., James, N. D. & Sculpher, M. J. 2018. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. European Urology Oncology, 1, (6) 449-458.